WeTrials
Recruiting

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)

What is this study?

This study tests a new oral medicine called VVD-133214, either alone or with other cancer therapies, for people with advanced solid tumors. Researchers want to see how safe the drug is and how well it blocks the growth of certain types of cancer.

Who can participate?

You might be able to join if you have an advanced solid tumor with specific genetic features known as MSI-high or dMMR, and can perform your daily activities. Depending on the treatment group, you may need to have tried certain prior treatments or be newly diagnosed.

What will happen?

You will take the study drug as a pill, and depending on your group, you may also receive other approved cancer drugs like pembrolizumab or bevacizumab. Your health and any side effects will be closely monitored by the medical team throughout the study.

Where and when?

This study is currently recruiting participants at locations in Arizona and California, United States.

Key Points
  • 1Testing a new cancer pill called VVD-133214
  • 2For adults with advanced solid tumors having specific genetic markers
  • 3Currently recruiting patients at select medical centers

Related video

Dr. Timothy Yap (MD Anderson): early results from this VVD-214 trial (AACR 2025)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorsColorectal Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.